Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care

NCT05088928 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Apixaban
DRUG: Rivaroxaban

Sponsor

Scotmann Pharmaceuticals

Collaborators

[object Object]